CSL Seqirus, a business of CSL (ASX: CSL), today announced expanded availability of influenza vaccine in the United States following the successful completion of its 2026/27 manufacturing campaign.

Washington, D.C., May 12, 2026 — The Pan American Health Organization (PAHO) today announced a historic agreement with CSL Seqirus aimed at securing a reserved share of pandemic influenza vaccines ...

MONTREAL, March 6, 2026 /CNW/ - CSL Seqirus has been awarded a new contract agreement to support the influenza pandemic preparedness plans of the Canadian government's Public Health Agency of Canada ...

CSL secures a major Canadian contract for cell-based flu vaccines while navigating an 81% profit drop and a $550M cost-saving restructuring plan. Australian biotech giant CSL has clinched a ...

The European Commission on Wednesday announced that Sanofi (SNY) has agreed to stop disparaging a rival flu vaccine developed by CSL Limited (CSLLY) after the French drugmaker faced an EU antitrust ...

April 23 (Reuters) - Australian biotech giant CSL ⁠extended ⁠losses on Thursday, lingering near decade ⁠lows, after the U.S. military scrapped its flu vaccine mandate, dealing another blow to the ...

Australian biotech giant CSL reported a 184 percent drop in net profit in the 2026 financial year, amid restructuring and lower flu vaccination rates in the United States. During the year, the company ...

CSL Ltd shares have lost about half their value over the past 12 months, briefly touching nine?year lows in early May 2026 as investors digest a planned demerger of its flu vaccine business and weaker ...

The news: CSL’s vaccine arm Seqirus has been awarded an advance order contract with the Public Health Agency of Canada to supply 15 million doses in the event that the World Health Organisation ...